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Abstract: Background: Antibiotic-resistant H. pylori was increasingly found in infected individuals,
which resulted in treatment failure and required alternative therapeutic strategies. Daphnetin,
a coumarin-derivative compound, has multiple pharmacological activities. Methods: The mechanism
of daphnetin on H. pylori was investigated focusing on its effect on cell morphologies, transcription
of genes related to virulence, adhesion, and cytotoxicity to human gastric epithelial (GES-1) cell
line. Results: Daphnetin showed good activities against multidrug resistant (MDR) H. pylori
clinical isolates, with minimal inhibitory concentration (MIC) values ranging from 25 to 100 µg/mL.
In addition, daphnetin exposure resulted in H. pylori morphological changes. Moreover, daphnetin
caused increased translocation of phosphatidylserine (PS), DNA damage, and recA expression, and
RecA protein production vs. control group. Of great importance, daphnetin significantly decreased
H. pylori adhesion to GES-1 cell line vs. control group, which may be related to the reduced expression
of colonization related genes (e.g., babA and ureI). Conclusions: These results suggested that daphnetin
has good activity against MDR H. pylori. The mechanism(s) of daphnetin against H. pylori were
related to change of membrane structure, increase of DNA damage and PS translocation, and decrease
of H. pylori attachment to GES-1 cells.
Keywords: Helicobacter pylori; daphnetin; mechanism of action; colonization
1. Introduction
Helicobacter pylori (H. pylori), a Gram-negative bacterium that specifically colonizes in the human
stomach, has developed numerous strategies to survive in the high acidity environment in the stomach
lumen [1]. It has been reported that this pathogen chronically infects over half of all humans [2].
Colonization of H. pylori can lead to gastritis and peptic ulcers, mucosa-associated lymphoid tissue
lymphoma, and gastric cancer [3]. Therefore, H. pylori has been categorized as a Class I carcinogen
by the World Health Organization (WHO) [4]. In addition, H. pylori infections are more common in
developing countries and are mostly developed during childhood [5]. Of note, anti-H. pylori therapy
has been used for decades, but the efficacy of the treatment has declined during the last decade because
of increasing antibiotic resistance [6,7]. In 2017, WHO listed 12 bacteria that threaten human health
the greatest, among which clarithromycin-resistant H. pylori was considered to be one of the high
priorities [8]. A recent review demonstrated that H. pylori resistance rate to clarithromycin was 28.9%,
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whereas the primary antibiotic resistance of H. pylori was metronidazole in China (around 70%) [9].
Therefore, new antibacterial agents against H. pylori are needed to overcome this concern.
Daphnetin (7,8-dihydroxycoumarin)—a major bioactive component extracted from the genus
Daphne as well as several other genera—is a coumarin-derivative compound of aromatic odor, with
structure comprising o-hydroxy cinamic acid lactones (Figure 1) [10]. In China, daphnetin has
been used clinically to treat Buerger’s disease for many years [11]. Its multiple pharmacological
activities, including anti-inflammatory, -diarrheal, -parasitic, -hypoxia, etc., have been reported [12,13].
Daphnetin exhibited selective cytotoxicity to human renal cell carcinoma cells, relative to noncarcinoma
proximal tubular cells [14]. So far, neither toxic effects [15] nor genetic toxicity [15,16] were found
in daphnetin. Therefore, it has attracted extensive research interests to investigate the activity and
mechanism(s) of daphnetin against MDR H. pylori.
In the current studies, we examined the antibacterial activity of daphnetin against 20 H. pylori
clinical isolates, including MDR strains, and investigated its anti-H. pylori mechanisms. Our findings
suggest that daphnetin may offer a significant advantage in the prevention of H. pylori infections.
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Figure 1. Structure of daphnetin (Molecular Weight 178.143 g/mol).
2. Results
2.1. Antibacterial Activity of Daphnetin Against H. pylori Strains
A total of 20 H. pylori strains isolated from human gastric antrum were used in this study
(Table S1). Daphnetin inh bited all the sted H. pylori str ins, rega dless of their resistance profiles to
other common used antibiotics, at concentrati ns ranging from 25 to 100 µg/mL (Table 1 and Table S1).
The percentage of clarithromyci resistance in the studied H. pylori strains was 25%, with MICs ranging
from 0.016 t 4 µg/mL (Table 1). Eighty-five percent of the clinical H. pylori strains were re istant to
metronidazole with MICs ranging from 4 to 256 µg/mL, and daphnetin still had good activity against
th se h ghly metronidazole res stant H. pylori strains with MICs of 25 µg/mL (Table 1 and Table S1).
H. pylori ATCC43504 strain was used as a quali y control with expected MICs of c arithromycin and
metronidazole (Table 1).
Table 1. Minimum inhibitory concentrations (MICs) of daphnetin, metronidazole, and clarithromycin
against H. pylori strains.
Antibiotics
MICs (µg/mL) Percent of
Resistance (%) b20 Clinical Isolates ATCC43504 a
Daphnetin 25–100 25 NA c
Clarithromycin 0.016–4 0.016 25%
Metronidazole 4–256 128 85%
a H. pylori ATCC43504 strain served as MIC quality control (metronidazole: 64–256 µg/mL; clarithromycin:
0.015–0.12 µg/mL). b Metronidazole: ≤ 8 µg/mL for susceptible and > 8 µg/mL for resistant; clarithromycin:
≤ 0.25 µg/mL for susceptible, 0.5 µg/mL for intermediate and > 0.5 µg/mL for resistant. c NA: not applicable.
2.2. Effect of Daphnetin on H. pylori Morphology
We first visualized the morphology of entire H. pylori cells by scanning electron microscopy
(SEM). Control cells without daphnetin exposure demonstrated smooth, homogenous cell surfaces
and rod-shaped morphotypes (Figure 2A,D). After exposure to daphnetin at sub-MIC concentrations
(e.g., 6.25 or 12.5 µg/mL) for three days, some H. pylori cells showed extensive surface damage
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(e.g., budding structures), heterogeneous populations of cells, and increased coccid forms in a
concentration-dependent manner (Figure 2B,E for daphnetin at 6.25 µg/mL exposure; 2C,F for
daphnetin at 12.5 µg/mL exposure). Transmission electron microscopy (TEM) images displayed
the organization of H. pylori with a clearly defined cytoplasm and cell membrane. The ultrastructural
characteristics of H. pylori cells without daphnetin exposure showed homogeneous cytoplasm
and intact cell membrane (Figure 3A–C). However, daphnetin-treated (at 12.5 µg/mL) H. pylori
cells showed visual morphological changes, including reduced bacterial size (relative diameter:
control:daphnetin exposure group = 1.00:0.77), rough outer membrane, granular-textured cytoplasm,
peculiar detachments between membrane and cytoplasm, numerous vesicles, and/or typical “holes”
attached to the inner membrane. In addition, vesicles emerged in ~40% H. pylori cells in the
daphnetin exposure group, while no vesicle was found in control group (Figure 3D–F). Taken
together, electron microscopy images showed that daphnetin exposed H. pylori had substantial visual
morphological changes.
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2.3. Daphnetin-Induced Membrane Changes
The extent of phosphatidylserine (PS) exposure on the outer membrane was determined
using annexi V. We observed that daphn tin at sub-MIC concentration (12.5 µg/mL) resulted in
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significant increased annexin V-mediated labeling of PS, from 5.93% to 56.99% (Table 2). These data
indicated that daphnetin could change H. pylori’s outer membrane structure. We also employed the
bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC) and propidium iodide (PI) dye to monitor
membrane polarity and permeability. As shown in Table 2, no significant fluorescence changes were
observed between control and daphnetin-treated H. pylori cells. Subsequently, we demonstrated that
protein leakage was slightly increased in daphnetin treated group vs. control group (Table 2). However,
these differences did not reach statistical significance. These results suggested that daphnetin treatment
led to outer membrane structure change, while had no significant effect on membrane permeability
and depolarization in H. pylori.
Table 2. Membrane changes induced by daphnetin.
Groups
Mean of the Positive Fluorescence± SD (%)
Protein Leakage
(µg/mL)PS Translocation MembranePermeability
Membrane
Depolarization
Control 5.93 ± 1.25 7.78 ± 0.62 9.26 ± 1.34 0.56 ± 0.01
Daphnetin
(12.5 µg/mL) 56.99 ± 5.78 * 5.06 ± 3.40 8.87 ± 2.71 0.60 ± 0.03
* P < 0.001 vs. control.
2.4. Daphnetin Caused DNA Damage
In order to determine whether daphnetin was able to cause DNA damage in H. pylori,
flow cytometry and confocal were used to detect terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) staining cells. As shown in Figure 4A, significant higher fluorescence signal was
observed in daphnetin-treated H. pylori cells vs. control (8.11% vs. 68.02% for control and daphnetin-
treated group, respectively). These results were confirmed with confocal analyses (Figure 4B). It is
well known that RecA is linked between DNA damage and membrane structure changes [17]. Thus,
we tested the transcription level of recA and found that recA expression was significantly increased
by daphnetin exposure as compared to untreated cells (Figure 4C). Corresponding to recA expression
results, RecA protein production was also significantly increased in the daphnetin exposure group
vs. control (66.9 ± 6.1 to 133.1 ± 6.1 for control and daphnetin-treated group, respectively; p < 0.001,
Figure S1).
2.5. Daphnetin Decreased H. pylori Adherence to Immortalized Human Gastric Epithelial Cell Line (GES-1)
and Inhibited Colonization-Associated Gene Expression
In order to investigate the effect of daphnetin on colonization, the expression of two key genes
(babA and ureI) related to colonization were measured in H. pylori by qRT-PCR. The transcriptions
of the two genes were significantly repressed by daphnetin exposure as compared to untreated cells
(Figure 5A,B). In addition, we tested the production of BabA and UreI protein by LC–MS/MS, and
found that consistent to the gene expression data, BabA protein level was also decreased in the
daphnetin exposure group (from 113.9 ± 10.8 to 86.1 ± 10.8, p < 0.05; Figure S2), while the UreI level
was below the limit of detection. Moreover, to test the adherence ability of H. pylori to the GES-1
cells, H. pylori cells with/without daphnetin exposure were labeled with fluorescein-isothiocyanate
(FITC) and analyzed by confocal microscopy. We demonstrated that daphnetin exposure significantly
decreased the adherence of H. pylori to the GES-1 cells vs. control group (Figure 5C). These results
suggested that daphnetin may prevent H. pylori colonization in human stomach.
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The expression of the study genes without daphnetin exposure was normalized as 1. Inhibitory effect
of daphnetin on adhesion of H. pylori to GES-1 cells (C). The level of adherence of H. pylori was detected
by confocal ( agnification: 600). All the data were presented as mean and standard deviations (SD).
* p < 0.05, ** p < 0.01 vs. control.
2.6. The Cytotoxic Effect of Daphnetin on GES-1
The cytotoxic effect of daphnetin to GES-1 cells in medium (with/without serum) was investigated
by using cell counting kit-8 (CCK-8) assay. The results showed that sub-MIC of daphnetin was well
tolerated by GES-1 cells and there was no significant cytotoxic difference under both conditions
(Table 3).
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Table 3. The cytotoxic effects of daphnetin to GES-1 cells in medium (with/without serum).
Groups Viability (mean± SD/%)
a
DMEM DMEM + 10% FBS b
Control 100.00 ± 7.79 100.00 ± 2.30
Daphnetin
12.5 µg/mL 84.43 ± 5.95 81.14 ± 11.52
a: The viability of control group without daphnetin exposure was normalized as 100%. b: DMEM: Dulbecco’s
modified Eagle’s medium; FBS: fetal bovine serum.
3. Discussion
The increasing prevalence of MDR H. pylori around the world has become one of the major
causes of treatment failure in H. pylori infections [18,19]. The European Committee on Antimicrobial
Susceptibility Testing (EUCAST) resistance breakpoints of clarithromycin and metronidazole to
H. pylori were >0.5 µg/mL f and >8 µg/mL, respectively [20]. The global H. pylori antibiotic resistance
rates were 17.2% for clarithromycin and 26.7% for metronidazole. In general, the resistance rate
in developing countries is higher than that in developed countries [7,19]. Of note, metronidazole
resistance rate of H. pylori isolated in the southeast coastal region of China is close to 100% according
to a recent report [21]. In our study, the resistance rates for clarithromycin and metronidazole were
much higher that the global H. pylori antibiotic resistance rates. According to the study from De
Francesco et al., the clarithromycin- and metronidazole-resistance levels can be further classified into
low level resistance (MICs from > 0.5 to ≤ 8 µg/mL for clarithromycin and from > 8 to ≤ 32 µg/mL
for metronidazole) and high level resistance (MICs from > 8 to 256 µg/mL for clarithromycin and
from > 32 to 256µg/mL for metronidazole) [22]. All the 20 clinical strains in our study were low
level resistance to clarithromycin and 50% (10/20) of clinical strains were high level resistance to
metronidazole (See Table S1). The similar result was reported by Bai et al., indicating that antibiotic
resistance in Chinese patients (MIC50 = 0.38 µg/mL for clarithromycin, and MIC50 = 128 µg/mL for
metronidazole) [23]. Our study demonstrated that daphnetin has anti-H. pylori activity, with MICs
ranging from 25 to 100 µg/mL, regardless of their resistance patterns to other antibiotics. Daphnetin
was also reported to have antibacterial activity against other bacterial species, including S. aureus,
E. coli, P. aeruginosa, and R. solanacearum [24,25]. However, the mechanism of daphnetin against bacteria
has not been well studied.
Apoptosis was always occurred when stimulated by appropriate trigger in both eukaryotic
multicellular organisms and in prokaryotic cells [26,27]. The cell morphology of apoptosis
includes morphological transition from spiral to coccoid, increased in electrondense bodies, appear
vacuoles [26,27]. Our morphological data were consistent with results of Cellini et al., who
demonstrated that H. pylori cells change from typical spiral morphology to coccoid form as a response
to environmental stress [28,29]. In addition, these phenomena were also similar with results of Shu
et al., who observed a reduction in size and empty bubble degeneration in the daphnetin treatment
group in synovial cells [30].
A stereotypical set of biochemical hallmarks of apoptosis (e.g., PS translocation, membrane
depolarization, and DNA damage) have been proved in both eukaryotic and prokaryotic
organisms [17,27,31,32]. In our experiments, we observed PS translocation and DNA damage
significantly increased after daphnetin exposure as compared to control group. It is well known
that DNA damage and membrane structure changes are the specific characteristics of apoptosis [33].
These phenotypes were also confirmed by other research groups studying prokaryotic organisms
during apoptosis [17,28]. Although we could not detect one of the phenotypes related to apoptosis
(e.g., membrane depolarization) in the current study [17]. The outcome may be related to decreasing
reactive oxygen species (ROS) formation by daphnetin exposure (daphnetin-treated vs. control:
73.8 ± 7.11% vs. 10.42 ± 2.42%), due to there is a positive interaction between ROS accumulation and
depolarization [34]. In addition, RecA plays a central role in the exhibition of these phenotypes [17],
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and we actually observed its expression significantly increased after daphnetin exposure. Therefore,
our observations suggested that daphnetin exposure could induce a non-typical apoptosis in H. pylori.
RecA not only mediates cell death, but also plays an important role during stomach
colonization [35]. For instance, RecA negatively regulates colonization-related babA gene
expression [35]. In our current studies, we observed recA gene expression and RecA protein
production were significantly increased by daphnetin exposure as compared to control. BabA is
the best-characterized adhesion protein in H. pylori, which contributes the bacterium to attach to the
glycosylated gastric epithelial cells [36]. Inconsistent with RecA’s function on babA expression, we
found that the transcription of babA and BabA protein production were significantly decreased with
daphnetin treatment vs. controls. UreI is a proton-gated urea channel and plays an important role
in H. pylori colonization on acidic stomach surface [37]. We found that urel gene was significantly
decreased with daphnetin exposure vs. control group by qRT-PCR. However, we could not detect
UreI protein expression in our study, which might be related to the limitation of our LC–MS/MS
analyses, as well as the solubility of UreI protein [37]. As babA and urel play important roles in cell
colonization, the decreased expression of these two genes may lead to decreased adherence of H. pylori
to cells. Consistently, decreased adherence of H. pylori to GES-1 cells was observed with daphnetin
exposure. In addition, we found no significant cytotoxicity of daphnetin to the GES-1 cell line, which
is in agreement with published data [14,16]. These results suggested that daphnetin may have ability
to prevent H. pylori colonization on the stomach.
4. Materials and Methods
4.1. Bacterial Strains and Materials
Twenty H. pylori strains from CAMS Collection Center of Pathogen Microorganisms (CCPM) were
isolated from gastric antrum in Beijing, China (see Table S1). H. pylori ATCC43504 was a standard strain
isolated from human gastric antrum in Australia. It is a metronidazole-resistant strain, while sensitive
to other clinical antibiotics (e.g., clarithromycin). For the isolation of H. pylori strains, gastric mucosal
specimens were collected, inoculated on agar plates containing 5% defibrinated sheep blood, and
cultured at 37 ◦C under microaerobic conditions (10% CO2, 5% O2, 85% N2) for 3 days [38]. The isolated
H. pylori strains were confirmed by standard biochemical tests (urease, catalase), 16S rRNA sequencing,
and morphological analyses. The study H. pylori strains were frozen (BHI media with 30% glycerine) in
cryobank tubes at −80 ◦C. Clarithromycin and metronidazole were purchased from National Institutes
for Food and Drug Control, Beijing, China. Vancomycin was purchased from INALCO SPA in Milano,
Lombardia, Italy. Trimethroprim, polymyxin B sulfate, amphotericin B, and cefsulodin sodium salt
were purchased from Sangon Biotech Co., Ltd., Shanghai, China. Daphnetin was purchased from
Meilun Biotech Co., Ltd., Dalian, China. β-cyclodextrin, fluorescein-isothiocyanate (FITC) and human
serum albumin (HSA) were purchased from Sigma, St. Louis, MO, USA. DMEM and FBS were
obtained from Gibco, Waltham, MA, USA.
4.2. Cell Cultures
Agar-based culture of H. pylori: Frozen H. pylori strains were revitalized and maintained
on Columbia blood agar plates containing selective antibiotics (e.g., vancomycin, trimethroprim,
polymyxin B sulfate, amphotericin B, and cefsulodin sodium salt), and cultured at 37 ◦C under
microaerobic conditions (10% CO2, 5% O2, 85% N2) for 3 days [38].
Liquid broth-based culture of H. pylori: H. pylori cells were swap from agar plate, resuspended
in Brucella broth containing 10% FBS and 1% vancomycin, and cultured at 37 ◦C under microaerobic
conditions (10% CO2, 5% O2, 85% N2) for 3 days [38].
GES-1, an immortalized human gastric epithelial cell line was cultured in DMEM medium
supplemented with 10% FBS in a humidified incubator [39].
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4.3. MICs of Daphnetin, Metronidazole, and Clarithromycin on H. pylori Strains
The antibacterial activities of daphnetin, metronidazole and clarithromycin against H. pylori were
examined by standard agar dilution test (CLSI [M45]). Briefly, a saline suspension equivalent to a
2.0 McFarland standard (about 108 CFU/mL) was prepared from a Mueller-Hinton agar plate plus
selective antibiotics [38]. The inoculum is replicated directly onto the antimicrobial agent-containing
agar dilution plates (daphnetin: 3.125–400 µg/mL; metronidazole: 1–512 µg/mL; clarithromycin:
0.015–8 µg/mL). The plates were incubated at 37 ◦C for 3 days. H. pylori ATCC43504 strain was used
as a control. The MIC was determined as the lowest concentration of drug showing no growth, a haze,
one discrete colony, or multiple tiny colonies [40].
4.4. H. pylori Morphology Analyses by SEM and TEM
The morphology of H. pylori with/without daphnetin exposure was performed by SEM and
TEM as previously reported with some modifications [41,42]. For SEM, H. pylori strains were
incubated with/without 6.25 or 12.5 µg/mL daphnetin for 3 days, then collected and fixed with 2.5%
glutaraldehyde. Postfixing, the samples were centrifuged to remove glutaraldehyde and resuspended
in phosphate buffer. The bacterial suspensions were spotted on a polished silicon wafer and allowed
to dry overnight in a biosafety cabinet. The samples were then coated with chromium before SEM
imaging. For TEM, H. pylori cells were exposed with/without 12.5 µg/mL of daphnetin for 3 days,
then collected and fixed with 2.5% glutaraldehyde at least 2 h at 4 ◦C. The fixed organisms were
washed and postfixed with 1% osmium tetroxide. Then the samples were washed, dehydrated in a
graded series of ethanol and embedded in Epon Araldite. Ultrathin sections containing the cells were
placed on copper grids, stained with uranyl acetate and lead citrate, observed, and photographed with
a TEM microscope (Hitachi, Tokyo, Japan).
4.5. Detection of Membrane Changes
H. pylori cells were grown as described in the ‘Cell culture’ section above. Briefly, H. pylori cells
were scraped from the Mueller-Hinton agar plates with or without daphnetin. To monitor the degree of
cell membrane structural changes [17], a TransDetect Annexin V-FITC/PI Cell Apoptosis Detection Kit
(Transgen Biotech, Beijing, China) was used. For membrane depolarization experiment [17], staining of
cells were performed using DiBAC (Invitrogen, Waltham, MA, USA). To determine the integrity of cell
membrane, a bicinchoninic acid (BCA) protein assay kit was used. Briefly, H. pylori cells (0.5 McFarland)
were cultured with or without daphnetin in Brucella broth for 24 h. The samples were centrifuged at
4 ◦C, the supernatants were treated with BCA assay reagent, and OD at 595 nm was measured [43].
4.6. Detection of DNA Damage
To detect DNA damage in H. pylori [44], a TransDetect In Situ Fluorescein TUNEL Cell Apoptosis
Detection Kit (Transgen Biotech, Beijing, China) was employed. Accuri C6 (BD, Franklin Lakes,
Germany) flow cytometer and LSM510 confocal (Zeiss, Oberkochen, Germany) were used to detect
the fluorescence signal changes. All flow cytometry data were collected using the Accuri C6 software.
At least 10,000 cells were collected and analyzed for each sample. Flow data were processed and
analyzed with CFlow Plus (BD, Franklin Lakes, Germany).
4.7. RNA Isolation and Quantitative Real-Time PCR
Briefly, H. pylori cells were incubated with/without 12.5 µg/mL daphnetin for 3 days,
then collected. Total RNA was isolated using an RNAprep pure Cell/Bacteria Kit (TianGen Biotech,
Beijing, China). Primers used in this study are listed in Table 4. Primer Premier 5 was used to design the
primers, and nucleotide search was performed based on Helicobacter pylori strain 26695 chromosome
locus (HP0071 for ureI; HP1243 for babA; and HP0153 for recA). A housekeeping gene 16S rRNA
was used as control [45]. qRT-PCR was performed on the 7500 fast using an SYBR Green Supermix,
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Life Technologies (AB & Invitrogen, Waltham, MA, USA). All assays were carried out at least in three
independent experiments in triplicates. Relative quantification was calculated by the ∆∆Ct method.
Table 4. The qRT-PCR primers used in this study.
Primers Sequence
ureI Forward: CCCCTGTAGAAGGTGCTGAAReverse: GCCGCATACAAGTAGGTGAAAC
babA Forward: AAGCCTATCAAATCCTCCAAACGReverse: TGGCGAGCAGTTATTATTCCCT
recA Forward: CTAAGAGGTTGGGCGTGGAReverse: CAATCCCTCCGCTTCTGGT
16s rRNA Forward: GTGCCAGCMGCCGCGGTAAReverse: GACTACHVGGGTATCTAATCC
4.8. Membrane Preparation and Proteomics by Liquid Chromatography–Mass Spectrometry/Mass
Spectrometry Analyses
The membrane fraction of H. pylori was prepared as described previously with
modifications [46,47]. In brief, H. pylori cells were harvested, washed in 20mM Tris-HCl (pH 7.5), and
pelleted twice by centrifugation (4000× g for 5 min). Bacterial cells were suspended in 20 mM Tris-HCl
(pH 7.5) and broken by repeated ultrasonication. The mixture was incubated at room temperature for
30 min. Cell debris were removed by centrifugation (9000× g for 20 min, 4 ◦C). Total membrane pellet
was collected by centrifugation (50,000× g for 20 min, 4 ◦C), then resuspended in 20 mM Tris-HCl
(pH 7.5) containing 2.0% (w/v) sodium lauryl sarcosine.
For shotgun proteomics [48], proteins were reduced by dithiothreitol at 95 ◦C for 5 min and
alkylated with iodoacetamide in dark for 1 h. Proteins were digested by sequencing grade modified
trypsin (1:50 w/w) overnight at 37 ◦C. Lastly, the sample was desalted by C18 reverse-phase ZipTip.
Standard shotgun proteomics techniques [48,49] were used to analyze the samples on a Thermo
Scientific Orbitrap Fusion Lumos equipped with a Thermo Scientific™ Nanospray Flex Ion Source and
nano-LC 1200 (Thermo Fisher Scientific, Bremen, Germany). Briefly, protein digests were enriched on a
trap column (Thermo Scientific™ Acclaim™ PepMap™ 100 C18 LC Column 164946 (75 µm × 20 mm))
and separated with another column (Thermo Scientific™ Acclaim™ PepMap™ 100 C18 LC Column
164943 (0.050 mm × 150 mm)). After sample loading, the gradient started from 2 to 8% of solvent
buffer (acetonitrile with 0.1% formic acid) for 1 min and then from 8 to 30% of solvent buffer for 69 min.
Then, the gradient quickly changed from 30 to 40% of solvent buffer for 14 min and from 40 to 100%
of solvent buffer for 1 min. In the final stage, the mobile phase was kept at 100% of solvent buffer
for 5 min. The eluted peptides were ionized online by electrospray ionization and transferred into
an Orbitrap Fusion Lumos mass spectrometer which was operated in the positive mode to measure
full scan Mass Spectrometry (MS) spectra (from m/z 350–1550 in the Orbitrap analyzer at resolution
R = 120,000 (MS1) and 15,000 (MS2). Higher-energy C-trap dissociation collision Energy was 32%.
For database analyses, unbiased data-dependent MS/MS acquisition was employed in
peptide/protein identification. These initial data-dependent runs were searched against H. pylori
ATCC 43504 and ATCC 26695 databases. Thermo Scientific™ Proteome Discoverer™ version 2.2
was used to analyze the quantitative data. The search parameters were set to MS accuracy 10 ppm,
MS/MS accuracy 0.02 Da, dynamic modification (protein terminus) for acetyl, dynamic modification
for oxidation, and static modification for carbamidomethyl.
4.9. H. pylori Adhesion Assays
To test the effect of daphnetin on H. pylori adherence to GES-1 cells, an adhesion assay was
performed as described previously with minor modifications [50]. Briefly, GES-1 cells were seeded on
cover glass bottom dishes and cultured at 37 ◦C with 5% CO2, until appropriate confluence (80–90%) was
reached. Samples were then infected with FITC-labeled H. pylori (with or without daphnetin exposure).
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For H. pylori FITC-labeling, a previously described method [51] with minor modifications was used.
Briefly, after 3 days incubation, H. pylori cells were harvested from agar plates with/without daphnetin
exposure, and resuspended in 1.0 mL of 0.15 M NaCl and 0.1 M Na2CO3, pH 9.0 in double-distilled
water by gentle pipetting. H. pylori cells were adjusted to 1.0 McFarland. Ten microliters of freshly
prepared 1% FITC in dimethyl sulfoxide (DMSO) were added to the suspension, then incubated for
1 h at room temperature in the dark. Bacteria were recovered by centrifugation at 3000× g for 5 min,
resuspended by gentle pipetting in 1.0 mL PBS supplemented with 5% inactivated fetal bovine serum,
0.2% BSA and 0.05% Tween 20. Add the FITC-labeled H. pylori cells into the dishes and incubated 4 h
at 37 ◦C. After incubation, three washes were performed with PBS to remove nonadherent bacteria.
LSM710 confocal was used to observe H. pylori adherence to GES-1 cells (Zeiss, Germany).
4.10. Cell Cytotoxicity Assays
Cell cytotoxicity was tested by the CCK-8 assay [52]. Briefly, GES-1 cells were plated in a 96-well
plate. After overnight incubation, the medium were replaced by with/without serum medium,
and then different concentrations of daphnetin were added. After 24 h of incubation, the cells were
treated with CCK-8 assay reagent, and OD at 450 nm was measured.
4.11. Statistical Analyses
Descriptive statistics of samples in the detection of the cell-related changes were presented
as means and SD from at least two independent experiments. Comparisons between control and
daphnetin-treated groups were performed via unpaired 2-tailed Student’s t-test. p < 0.05 was
considered statistically significant.
5. Conclusions
In conclusion, the anti-H. pylori activity of daphnetin and relevant mechanisms of its action were
reported in the current study. Daphnetin exhibited anti-MDR H. pylori activities. The mechanisms
of its action attributed to induce membrane structure changes, DNA damage, and increase RecA
expression. In addition, daphnetin exposure resulted with decreased colonization related gene
expression (e.g., babA and urel) and adherence to GES-1 cells with no significant cytotoxicity to
the cell line (Figure 6). Taken together, these results suggested that daphnetin has a potential to be an
effective anti-H. pylori agent. Future studies, including in vivo anti-H. pylori activity evaluation and
synthesis of daphnetin-derivatives with better biological activity, are expected.
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urel. Lower babA and urel transcription, and their respective protein production could reduce H. pylori
adherence to GES-1 cells. Moreover, daphnetin exhibited effect on membrane changes (e.g., outer
membrane structural change and increased PS exposure). In the current study, no significant impact
of daphnetin on membrane permeability and depolarization was observed (dotted line indicates no
statistical significance between control and daphnetin exposure groups).
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H. pylori with/without daphnetin exposure.
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